Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04746794 · ClinicalTrials.gov registry record · NA
Early Detection of GEnetic Risk (EDGE)
A NA study of Genetic Predisposition, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 20,184
- Enrollment target
- 2
- Study locations
NCT04746794: Completed NA study of Genetic Predisposition, sponsored by University of Washington.
NCT04746794 is a NA study of Genetic Predisposition that has completed, run by University of Washington. The registered enrollment target is 20,184 participants, above the 2,078-participant average among 14 other Genetic Predisposition trials with a reported enrollment target (871% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04746794, a NA study of Genetic Predisposition, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 20,184 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A "previvor" plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.
Primary Outcome
Fraction of the active clinic patient population that completed screening
Conditions Studied
Interventions
- BEHAVIORAL Population-level screening
Study Locations (2)
Montana
- Billings Clinic - Billings
Washington
- MultiCare Health System - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,184 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2023-06-01 |
| Phase | NA |
What the finished NCT04746794 record still lists
NCT04746794 is an interventional study that assigns participants to a tested intervention. Its 20,184 participants enrollment target places it among the larger protocols in the corpus, above the 2,078-participant average among 14 other Genetic Predisposition trials with a reported enrollment target (871% higher).
The record links to 1 condition, with Genetic Predisposition appearing as the primary indexed condition, and to 1 intervention - of which Population-level screening is the first listed.
NCT04746794 reports a single indexed study location in Montana, Washington.
Frequently Asked Questions
What is clinical trial NCT04746794 about?
NCT04746794 is a clinical study titled "Early Detection of GEnetic Risk (EDGE)". The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A "previvor" plan will be created to assist patients and their providers in completing the appr...
What is the current status of trial NCT04746794?
This trial is currently completed. It is a NA study. The enrollment target is 20,184 participants. The study started on 2020-09-25. Estimated completion is 2023-06-01.
What conditions does trial NCT04746794 study?
This clinical trial studies the following conditions: Genetic Predisposition.
What interventions are being tested in trial NCT04746794?
The interventions under investigation include: Population-level screening (BEHAVIORAL).
Who is sponsoring clinical trial NCT04746794?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04746794 being conducted?
This trial has 2 study locations across Montana, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Predisposition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04746794's enrollment target sits among peer trials
20,184 1st of 14 higher than 14 of 14 other Genetic Predisposition trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Predisposition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
RECRUITING · NA
-
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
RECRUITING · NA
-
Genetic Information Assistant in Telegenetics
RECRUITING · NA
-
Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
ACTIVE NOT RECRUITING · NA
-
Overcoming Barriers to Accessing Genetic Medicine
ACTIVE NOT RECRUITING · NA
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI